Monday, 2021/06/07, 17:00
Bio: Dr. Larry J. Suva, originally from Melbourne, Australia, graduated as PhD in Medicine from the University of Melbourne in 1989. He did postdoctoral research at Merck during the development of the bisphosphonate (Fosamax) before joining the faculty of Harvard Medical School in 1992. Dr. Suva’s entire research focus is on the skeletal consequences of disease. These interests include breast cancer bone metastasis and multiple myeloma as well as fracture healing, bone regeneration, bone anabolism, rare bone diseases and bone infections. Current research efforts include a focus on the development of large animal pre-clinical models of rare bone disease that have the potential to change the study of bone turnover as well as bone physiology, and provide novel insight into future therapeutic directions that target regulatory pathways important for bone physiology. He is currently Professor and Department Head of Veterinary Physiology and Pharmacology at Texas A&M University, College Station, TX, USA. Peer-reviewed published work
Abstract: The use of genetic engineering has increased significantly in recent years, particularly with the wide acceptance of the CRISPR-Cas9 genome editing technology. The wide application of genome editing techniques provides a unique opportunity for musculoskeletal investigators to consider the examination of rare (and other) disease phenotypes in domestic animals. This idea is particularly important when considering the development of domestic animal (livestock) models of rare human bone disorders in which the bone remodeling process parallels that observed in humans. Certainly murine studies have significantly contributed to our understanding of human physiology yet it is also apparent that mice frequently respond to experimental interventions in ways that differ markedly from human responses. In a wide variety of experimental settings, we have developed ovine models of rare human disorders such as hypophosphatasia (HPP) and Progressive Pseudorheumatoid Arthropathy of Childhood (PPAC). The models provide opportunities to study disease progression but also provide unique tools with which to examine experimental therapeutic efficacy in a system that better models humans than mice. Similarly, we (and others) have utilized horses as a model to study non-bone effects of bisphosphonate treatment. We have a strategic focus on developing large animal models of specific human bone disorders that are not answered or not possible to answer in rodents.
Website: Prof. Dr. Larry J. Suva
Host: Prof. Dr. phil. nat. Willy Hofstetter, Program Bone & Joint, Hofstetter Lab, Department for BioMedical Research, University of Bern